Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLYIPA)

• Drug Name: SGT-53 Drug Info
• Synonyms: P53 gene stimulator (solid tumor), Synergene Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 2	[1]
Recurrent glioblastoma	2A00.00	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMLYIPA

Molecule-Related Drug Atlas

Drug(s) Targeting Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Contusugene ladenovec	DMN9ETB	Oral cancer	2B6E	Phase 3	[5]
QPI-1002	DMDU5Y2	Renal transplantation	NE84	Phase 3	[6]
Thymoquinone	DMVDTR2	Polycystic ovarian syndrome	5A80.1	Phase 2/3	[7]
APG-115	DMIFA0L	Prolymphocytic leukaemia	2A82.1	Phase 2	[1]
APR-246	DMNFADH	Ovarian cancer	2C73	Phase 2	[8]
Ad-p53	DMJSWXL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
Kevetrin	DMFO6MH	Ovarian cancer	2C73	Phase 2	[1]
INGN-225	DMF7J6D	Head and neck cancer	2D42	Phase 2	[10]
ALT-801	DM9KL7P	Acute myeloid leukaemia	2A60	Phase 2	[11]
ISA-P53-01	DMQ5EYJ	Colorectal cancer	2B91.Z	Phase 1/2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cellular tumor antigen p53 (TP53)	TT7SBF5	P53_HUMAN	Stimulator	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02340156) Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.
• [4] Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
• [5] A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
• [8] APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.
• [9] Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
• [10] INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
• [11] Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
• [12] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.